(Q33716122)

28 July 2017

1 reference

title

Protein tyrosine kinase inhibitors as novel therapeutic agents (English)

1 reference

28 July 2017

Levitzki A

1

1 reference

28 July 2017

1 May 1999

1 reference

Pharmacology & Therapeutics

28 July 2017

1 reference

28 July 2017

82

1 reference

28 July 2017

231-239

1 reference

28 July 2017

2-3

1 reference

PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrphostins suppress the growth of psoriatic keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Crystal structure of the tyrosine kinase domain of the human insulin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Protein tyrosine phosphorylation mediates TNF-induced endothelial-neutrophil adhesion in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Signal-transduction therapy. A novel approach to disease management

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Targeting signal transduction for disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Targeting signal transduction for disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrosine kinase inhibition: an approach to drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Epidermal-growth-factor-dependent activation of the src-family kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

The pathogenesis of atherosclerosis--an update

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

The pathogenesis of atherosclerosis (first of two parts)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Crystal structure of the Src family tyrosine kinase Hck

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900066-7

7 January 2021

10.1016/S0163-7258(98)00066-7

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10454200